Key clinical point: Serum levels of collagen metabolites show promising signs of being biomarkers for disease activity in axial spondyloarthritis (axSpA) patients.
Major finding: The products of all four collagens that could serve as biomarkers – C1M, C2M, C3M, and C4M2 – were found at higher levels in axSpA patients, compared with controls.
Study details: A cross-sectional study of collagen products in 193 recently diagnosed axSpA patients and 100 asymptomatic controls.
Disclosures: Two of the authors acknowledged being employees of fibrosis biomarker developer Nordic Bioscience; another researcher acknowledged being a stockholder. No additional conflicts of interest were reported.
Hušáková M et al. Sci Rep. 2019 Aug 2. doi: 10.1038/s41598-019-47502-z